AIP
ZVRA icon

Ameritas Investment Partners’s Zevra Therapeutics ZVRA Stock Holding History

Ameritas Investment Partners’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.8K Hold
4,591
– – ﹤0.01% 2181
2025
Q4 		$41.1K Hold
4,591
– – ﹤0.01% 2255
2025
Q3 		$43.7K Sell
4,591
-950
-17% -$9.53K ﹤0.01% 2226
2025
Q2 		$48.8K Buy
5,541
+1,280
+30% +$10.4K ﹤0.01% 2196
2025
Q1 		$31.9K Hold
4,261
– – ﹤0.01% 2351
2024
Q4 		$35.5K Hold
4,261
– – ﹤0.01% 2382
2024
Q3 		$29.6K Buy
4,261
+1,397
+49% +$9.48K ﹤0.01% 2464
2024
Q2 		$14K Hold
2,864
– – ﹤0.01% 2784
2024
Q1 		$16.6K Hold
2,864
– – ﹤0.01% 2636
2023
Q4 		$18.8K Hold
2,864
– – ﹤0.01% 2603
2023
Q3 		$13.8K Hold
2,864
– – ﹤0.01% 2696
2023
Q2 		$14.6K Buy
+2,864
New +$15.4K ﹤0.01% 2723
2022
Q2 		– Sell
-2,241
Closed -$11K – 3258
2022
Q1 		$11K Hold
2,241
– – ﹤0.01% 2776
2021
Q4 		$20K Hold
2,241
– – ﹤0.01% 2662
2021
Q3 		$21K Hold
2,241
– – ﹤0.01% 2678
2021
Q2 		$29K Buy
+2,241
New +$24.1K ﹤0.01% 2536

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Ameritas Investment Partners's ZVRA Position: Q1 2026 in Review

Ameritas Investment Partners held its Zevra Therapeutics (ZVRA) position steady in Q1 2026 at 4,591 shares worth $42.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2181.

Ameritas Investment Partners first reported a position in ZVRA in Q2 2021 and has held it in 16 quarters since. The position peaked at $48.8K in Q2 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Ameritas Investment Partners held 4,591 shares of Zevra Therapeutics worth $42.8K as of Q1 2026.
  • Ameritas Investment Partners left its Zevra Therapeutics share count unchanged in Q1 2026.
  • Zevra Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2181 holding.
  • Ameritas Investment Partners first reported a position in Zevra Therapeutics in Q2 2021 and has held it in 16 quarters since.
  • Ameritas Investment Partners's Zevra Therapeutics position peaked at $48.8K in Q2 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.